Progestogens and breast cancer risk: The role of hormonal contraceptives and hormone replacement therapy

Journal of Family Planning and Reproductive Health Care

Volumn 29, Issue 4, 2003, Pages 185-187

  Marsden, Jo ^a   A'Hern, Roger ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; LEVONORGESTREL; TAMOXIFEN;

BREAST CANCER; CANCER RISK; DRUG EFFECT; DRUG USE; FEMALE; GENE MUTATION; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MITOGENESIS; MORTALITY; ONCOGENE; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL TIME;

AGE FACTORS; BREAST NEOPLASMS; CONTRACEPTIVES, ORAL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; PROGESTERONE CONGENERS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; RISK FACTORS; TIME FACTORS; WOMEN'S HEALTH;

EID: 0142024152     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118903101198042     Document Type: Review

References (26)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321-333.
3. Women's Health Initiative (WHI) HRT Update 2002. www.nhlbi.nih.gov
4. Chlebowski RT, Hendrix SL, Langer RD, et al. for the WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative Randomised Trial. JAMA 2003; 289: 3243-3253.
5. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427.
6. Million Women Study Collaborators. Patterns of use of hormone replacement therapy in one million women in Britain, 1996-2000. Br J Obstet Gynaecol 2002; 109: 1319-1330.
7. Lundström E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002; 186: 717-722.
8. Collaborative Group on Hormonal Factors for Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis from 51 individual epidemiological studies. Lancet 1997; 350: 1047-1060.
9. Nanda K, Bastian LA, Schultz K. Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am J Obstet Gynecol 2002; 186: 325-334.
10. Kollias J, Murphy CA, Elston CW, et al. The prognosis of small primary breast cancers. Eur J Cancer 1999; 35: 908-912.
11. Col NF, Kirota LK, Orr RK, et al. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol 2001; 19: 2357-2363.
12. Marsden J, Sacks NPM, Baum M, et al. Are randomised trials of hormone replacement therapy in symptomatic breast cancer patients feasible? Fert Steril 2000; 73: 292-299.
13. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999; 130: 262-269.
14. Hofseth LJ, Raafat Am, Osuch JR, et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999; 84: 4559-4565.
15. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-1727.
16. Althuis MD, Brogan DR, Coates RJ, et al. Hormonal content and potency of oral contraceptives and breast cancer risk among young women. Br J Cancer 2003; 88: 50-57.
17. Dumeaux V, Alsaker E, Lund E. Breast cancer and specific types of oral contraceptives: a large Norwegian cohort study. Int J Cancer 2003; 105: 844-850.
18. Narod SA, Dube MP, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002; 94: 1773-1779.
19. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998; 339: 424-428.
20. Isaksson E, von Scholtz E, Odlind V, et al. Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 2001: 65: 163-169.
21. Luukkainen T, Lähteenmäki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann Med 1990; 22: 85-90.
22. Gram IT, Funkhouser E, Nordgård L, et al. Oral contraceptive use and mammographic patterns. Eur J Cancer Prev 2002; 11: 265-270.
23. Dupont WD, Page DL, Parl FF, et al. Estrogen replacement therapy in women with a history of proliferative breast disease. Cancer 1999; 85:1277-1283.
24. Cuzick J, Powles T, Veronsesi U, et al. Overview of the main outcomes in breast cancer prevention trials. Lancet 2003; 361: 296-300.
25. Rohan TE, Miller AB. A cohort study of oral contraceptive use and risk of benign breast disease. Int J Cancer 1999; 82: 191-196.
26. Friedenreich CM, Bryant HE, Alexander F, et al. Risk factors for benign proliferative breast disease. Int J Epidemiol 2000; 29: 637-644.